The Trial of Antihypertensive Interventions and Management (TAIM) Study

Adequate Weight Loss, Alone and Combined With Drug Therapy in the Treatment of Mild Hypertension

Sylvia Wassertheil-Smoller, M. Donald Blaufox, Albert S. Oberman, Herbert G. Langford, Barry R. Davis, Judith Wylie-Rosett

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

This report examines the effect of weight loss, alone and in combination with drugs, on diastolic blood pressure change in the Trial of Antihypertensive Interventions and Management (TAIM), which is a randomized, multicenter, placebo-controlled clinical trial of drug and diet combinations in the treatment of mild hypertension among 787 patients. Diastolic blood pressure drop (11.6 mm Hg) at 6 months among those patients who were randomized to weight reduction and placebo drug treatment was greater among those who lost 4.5 kg or more, than the 7—mm Hg drop for those who lost less than 2.25 kg or for the placebotreated control group, and it was statistically equivalent to the reduction achieved by 25 mg of chlorthalidone or 50 mg of atenolol (11.1— and 12.4—mm Hg drop, respectively). Weight loss potentiated effects of drugs, with reductions of 18.4 mm Hg, for those patients who were taking atenolol and had a 4.5-kg or more weight loss, and of 15.4 mm Hg, for those patients who were taking chlorthalidone and had at least a 2.25-kg weight loss. We concluded that effective weight loss ( ≥4.5 kg) lowers blood pressure similarly to low-dose drug therapy and potentiates drug effects, with the apparent 4.5-kg threshold being lowered to 2.25 kg for those patients who receive chlorthalidone.

Original languageEnglish (US)
Pages (from-to)131-136
Number of pages6
JournalArchives of Internal Medicine
Volume152
Issue number1
DOIs
StatePublished - 1992

Fingerprint

Antihypertensive Agents
Weight Loss
Chlorthalidone
Hypertension
Drug Therapy
Blood Pressure
Atenolol
Drug Combinations
Therapeutics
Placebos
Pharmaceutical Preparations
Controlled Clinical Trials
Diet
Control Groups

ASJC Scopus subject areas

  • Internal Medicine

Cite this

The Trial of Antihypertensive Interventions and Management (TAIM) Study : Adequate Weight Loss, Alone and Combined With Drug Therapy in the Treatment of Mild Hypertension. / Wassertheil-Smoller, Sylvia; Blaufox, M. Donald; Oberman, Albert S.; Langford, Herbert G.; Davis, Barry R.; Wylie-Rosett, Judith.

In: Archives of Internal Medicine, Vol. 152, No. 1, 1992, p. 131-136.

Research output: Contribution to journalArticle

Wassertheil-Smoller, Sylvia ; Blaufox, M. Donald ; Oberman, Albert S. ; Langford, Herbert G. ; Davis, Barry R. ; Wylie-Rosett, Judith. / The Trial of Antihypertensive Interventions and Management (TAIM) Study : Adequate Weight Loss, Alone and Combined With Drug Therapy in the Treatment of Mild Hypertension. In: Archives of Internal Medicine. 1992 ; Vol. 152, No. 1. pp. 131-136.
@article{c51638587fbc492ab33203dc01182e0a,
title = "The Trial of Antihypertensive Interventions and Management (TAIM) Study: Adequate Weight Loss, Alone and Combined With Drug Therapy in the Treatment of Mild Hypertension",
abstract = "This report examines the effect of weight loss, alone and in combination with drugs, on diastolic blood pressure change in the Trial of Antihypertensive Interventions and Management (TAIM), which is a randomized, multicenter, placebo-controlled clinical trial of drug and diet combinations in the treatment of mild hypertension among 787 patients. Diastolic blood pressure drop (11.6 mm Hg) at 6 months among those patients who were randomized to weight reduction and placebo drug treatment was greater among those who lost 4.5 kg or more, than the 7—mm Hg drop for those who lost less than 2.25 kg or for the placebotreated control group, and it was statistically equivalent to the reduction achieved by 25 mg of chlorthalidone or 50 mg of atenolol (11.1— and 12.4—mm Hg drop, respectively). Weight loss potentiated effects of drugs, with reductions of 18.4 mm Hg, for those patients who were taking atenolol and had a 4.5-kg or more weight loss, and of 15.4 mm Hg, for those patients who were taking chlorthalidone and had at least a 2.25-kg weight loss. We concluded that effective weight loss ( ≥4.5 kg) lowers blood pressure similarly to low-dose drug therapy and potentiates drug effects, with the apparent 4.5-kg threshold being lowered to 2.25 kg for those patients who receive chlorthalidone.",
author = "Sylvia Wassertheil-Smoller and Blaufox, {M. Donald} and Oberman, {Albert S.} and Langford, {Herbert G.} and Davis, {Barry R.} and Judith Wylie-Rosett",
year = "1992",
doi = "10.1001/archinte.1992.00400130141018",
language = "English (US)",
volume = "152",
pages = "131--136",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - The Trial of Antihypertensive Interventions and Management (TAIM) Study

T2 - Adequate Weight Loss, Alone and Combined With Drug Therapy in the Treatment of Mild Hypertension

AU - Wassertheil-Smoller, Sylvia

AU - Blaufox, M. Donald

AU - Oberman, Albert S.

AU - Langford, Herbert G.

AU - Davis, Barry R.

AU - Wylie-Rosett, Judith

PY - 1992

Y1 - 1992

N2 - This report examines the effect of weight loss, alone and in combination with drugs, on diastolic blood pressure change in the Trial of Antihypertensive Interventions and Management (TAIM), which is a randomized, multicenter, placebo-controlled clinical trial of drug and diet combinations in the treatment of mild hypertension among 787 patients. Diastolic blood pressure drop (11.6 mm Hg) at 6 months among those patients who were randomized to weight reduction and placebo drug treatment was greater among those who lost 4.5 kg or more, than the 7—mm Hg drop for those who lost less than 2.25 kg or for the placebotreated control group, and it was statistically equivalent to the reduction achieved by 25 mg of chlorthalidone or 50 mg of atenolol (11.1— and 12.4—mm Hg drop, respectively). Weight loss potentiated effects of drugs, with reductions of 18.4 mm Hg, for those patients who were taking atenolol and had a 4.5-kg or more weight loss, and of 15.4 mm Hg, for those patients who were taking chlorthalidone and had at least a 2.25-kg weight loss. We concluded that effective weight loss ( ≥4.5 kg) lowers blood pressure similarly to low-dose drug therapy and potentiates drug effects, with the apparent 4.5-kg threshold being lowered to 2.25 kg for those patients who receive chlorthalidone.

AB - This report examines the effect of weight loss, alone and in combination with drugs, on diastolic blood pressure change in the Trial of Antihypertensive Interventions and Management (TAIM), which is a randomized, multicenter, placebo-controlled clinical trial of drug and diet combinations in the treatment of mild hypertension among 787 patients. Diastolic blood pressure drop (11.6 mm Hg) at 6 months among those patients who were randomized to weight reduction and placebo drug treatment was greater among those who lost 4.5 kg or more, than the 7—mm Hg drop for those who lost less than 2.25 kg or for the placebotreated control group, and it was statistically equivalent to the reduction achieved by 25 mg of chlorthalidone or 50 mg of atenolol (11.1— and 12.4—mm Hg drop, respectively). Weight loss potentiated effects of drugs, with reductions of 18.4 mm Hg, for those patients who were taking atenolol and had a 4.5-kg or more weight loss, and of 15.4 mm Hg, for those patients who were taking chlorthalidone and had at least a 2.25-kg weight loss. We concluded that effective weight loss ( ≥4.5 kg) lowers blood pressure similarly to low-dose drug therapy and potentiates drug effects, with the apparent 4.5-kg threshold being lowered to 2.25 kg for those patients who receive chlorthalidone.

UR - http://www.scopus.com/inward/record.url?scp=0026570895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026570895&partnerID=8YFLogxK

U2 - 10.1001/archinte.1992.00400130141018

DO - 10.1001/archinte.1992.00400130141018

M3 - Article

VL - 152

SP - 131

EP - 136

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 1

ER -